AB030. Evolution of Phosphodiesterase Type 5 Inhibitors

Translational Andrology and Urology - China
doi 10.21037/tau.2016.s030
Full Text
Abstract

Available in full text

Date
Authors
Publisher

AME Publishing Company

Related search

Phosphodiesterase Type 5 Inhibitors in the Treatment of Pulmonary Arterial Hypertension

Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology
2010English

Phosphodiesterase Type 5 Inhibitors: A Biochemical and Clinical Correlation Survey

International Journal of Impotence Research
Urology
2003English

Daily Use of Phosphodiesterase Type 5 Inhibitors as Prevention for Recurrent Priapism

Revista da Associacao Medica Brasileira
Medicine
2017English

Phosphodiesterase-5 Inhibitors: Emerging Nephroprotective Drugs

Anatolian journal of cardiology
Cardiovascular MedicineCardiology
2015English

Quantitative Risk-Benefit Analysis of Oral Phosphodiesterase Type 5 Inhibitors on Erectile Dysfunction Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Usage and Perceptions of Phosphodiesterase Type 5 Inhibitors Among the Male Partners of Infertile Couples

Clinical and Experimental Reproductive Medicine
Reproductive Medicine
2016English

Phenanthrenes From Eulophia Macrobulbon as Novel Phosphodiesterase-5 Inhibitors

Natural Product Communications
PharmacologyComplementaryPlant ScienceAlternative MedicineMedicineDrug Discovery
2017English

Therapeutic Utility of Phosphodiesterase Type I Inhibitors in Neurological Conditions

Frontiers in Neuroscience
Neuroscience
2011English

Phosphodiesterase Type 5 Inhibitors Increase Herceptin Transport and Treatment Efficacy in Mouse Metastatic Brain Tumor Models

PLoS ONE
Multidisciplinary
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy